The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
第一作者:
K,Bajou
第一单位:
Laboratory of Tumor and Developmental Biology, University of Liège, Tour de Pathologie (B23), B-4000 Liège, Belgium.
作者:
医学主题词
血管生成抑制剂(Angiogenesis Inhibitors);动物(Animals);内肽酶类(Endopeptidases);内皮, 血管(Endothelium, Vascular);纤维蛋白溶酶(Fibrinolysin);角蛋白细胞(Keratinocytes);小鼠(Mice);小鼠, 突变型(Mice, Mutant Strains);肌肿瘤(Muscle Neoplasms);肿瘤侵润(Neoplasm Invasiveness);肿瘤, 实验性(Neoplasms, Experimental);新生血管化, 病理性(Neovascularization, Pathologic);纤溶酶原激活物抑制物1(Plasminogen Activator Inhibitor 1);蛋白质结合(Protein Binding);玻连蛋白(Vitronectin)
DOI
10.1083/jcb.152.4.777
PMID
11266468
发布时间
2024-09-22
- 浏览40
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



